Sara Eshelman
Principal @ Spero Ventures
New York, United States
Sara Eshelman is a Series A investor at Spero Ventures in New York focused on Health Care and Biotechnology. Sara Eshelman is the Principal at Spero Ventures.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 71%
Last updated:
For AI agents: llms.txt
Industries Sara Eshelman invests in
Stages Sara Eshelman invests in
Countries Sara Eshelman invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 3 (43%)
- Biotechnology 3 (43%)
- Medical 2 (29%)
- Artificial Intelligence 2 (29%)
- B2B 1 (14%)
Stage
- Series A 5 (71%)
- Series B 2 (29%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Tiny Health is the leading microbiome health platform for people tackling chronic conditions or looking to optimize overall health. Tiny Health’s Gut Health Test is the first-ever at-home gut microbiome test for pregnant moms and babies to use shotgun metagenomics, and the company now also offers tests for older children and adults, as well asVaginal Health Tests.To date, 30,000 families have trusted Tiny Health to correct imbalances in the gut and vaginal microbiome, and optimize their lifelong health. By taking evidence-based action steps from a dietary, supplement and lifestyle based on personalized results, we've helped people reduce severe symptoms and in some cases even reverse chronic conditions. Tiny Health's team includes top scientists, physicians, and microbiologists from Mayo Clinic, Johns Hopkins, Stanford, WashU, Cornell, and Harvard Medical School. For more information, visit tinyhealth.com and poweredbytiny.com | $33M / Series B / Sep 29, 2026 | ||
| Persist assist pharmaceutical companies in developing long-acting formulations 50% faster. Because the formulation development process is manual and relies on scientific intuition, it takes a pharmaceutical company 5-10 years to develop a long acting formulation for a drug. This effort is divided into five years of pre-clinical development and fiveyears of clinical testing. Their goal is to use machine learning and automation to reduce the time required for pre-clinical formulation development to three months, making the formulation development process 50% faster. | $12M / Series A / Mar 19, 2025 | ||
| Aralez Bio uses engineered enzymes to make valuable products in a sustainable way.The company has invented a novel enzymatic method for synthesizing noncanonical amino acids (ncAAs) also called unusual or unnatural amino acids. Its proprietary approach enables over 100 ncAAs to be synthesized with perfect enantiopurity in just a single step, withwater as the only byproduct | $12M / Series A / Oct 29, 2024 | ||
| Tiny Health is the leading microbiome health platform for people tackling chronic conditions or looking to optimize overall health. Tiny Health’s Gut Health Test is the first-ever at-home gut microbiome test for pregnant moms and babies to use shotgun metagenomics, and the company now also offers tests for older children and adults, as well asVaginal Health Tests.To date, 30,000 families have trusted Tiny Health to correct imbalances in the gut and vaginal microbiome, and optimize their lifelong health. By taking evidence-based action steps from a dietary, supplement and lifestyle based on personalized results, we've helped people reduce severe symptoms and in some cases even reverse chronic conditions. Tiny Health's team includes top scientists, physicians, and microbiologists from Mayo Clinic, Johns Hopkins, Stanford, WashU, Cornell, and Harvard Medical School. For more information, visit tinyhealth.com and poweredbytiny.com | $8.5M / Series A / Mar 05, 2024 | ||
| OOVA is a fertility diagnostic company that spun out from Mount Sinai Hospital in New York City. Using patent pending biochemistry and artificial intelligence, OOVA learns a woman’s fertility profile by accurately measuring key hormones over time through daily urine samples. By monitoring this critical balance of hormones, OOVA can help a woman getpregnant, identify reasons she is having trouble getting pregnant, and even expose reproductive health issues like PCOS. | $10.3M / Series A / Jun 12, 2023 | ||
| Hyro creates plug-and-play conversational AI assistants by seamlessly ingesting data on digital channels to allow users to interact with information via voice or chat simply and intuitively, allowing for increased engagement and conversions. Unlike existing solutions, Hyro provides organisations with frictionless deployment and maintenanceprocesses by automatically building a knowledge graph out of their existing content without any integration, playbooks, or training data. | $20M / Series B / May 31, 2023 | ||
| Hyro creates plug-and-play conversational AI assistants by seamlessly ingesting data on digital channels to allow users to interact with information via voice or chat simply and intuitively, allowing for increased engagement and conversions. Unlike existing solutions, Hyro provides organisations with frictionless deployment and maintenanceprocesses by automatically building a knowledge graph out of their existing content without any integration, playbooks, or training data. | $10.5M / Series A / May 25, 2021 |
Co-Investors
About Spero Ventures
Spero Ventures makes venture investments in the things that make life worth living - wellbeing; sustainability; learning, work, and play.
Spero Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Andrew Parker
General Partner
|
|||
|
Brandon Walker
Investor
|
|||
Marc Tarpenning
Venture Partner
|
|||
|
Sara Eshelman
Principal
|
|||
Shripriya Mahesh
Co-Founder and General Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Sara Eshelman invest in?
Sara Eshelman invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Sara Eshelman?
Public channels for Sara Eshelman include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Sara Eshelman last invest?
The most recent investment recorded for Sara Eshelman closed in Sep 2026. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
